Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RECQL | P46063 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30018981 | 1.00 | RAB9A (0.64) | RAB9ANPC1RECQLALDH1A1LMNA | |
| SCHEMBL22069615 | 0.85 | RAB9A (0.58) | RAB9ANPC1RECQLALDH1A1LMNA | |
| SCHEMBL16861185 | 0.82 | NPC1 (0.72) | RAB9ANPC1RECQLALDH1A1LMNA | |
| SCHEMBL171941 | 0.82 | NPC1 (0.72) | RAB9ANPC1RECQLALDH1A1LMNA | |
| SCHEMBL10582384 | 0.82 | RAB9A (0.54) | RAB9ANPC1RECQLALDH1A1LMNA | |
| SCHEMBL13735554 | 0.81 | KMT2A (0.41) | RAB9ANPC1RECQLALDH1A1LMNA | |
| SCHEMBL3464612 | 0.80 | NPC1 (0.79) | RAB9ANPC1RECQLALDH1A1LMNA | |
| SCHEMBL30159613 | 0.80 | ALDH1A1 (0.79) | RAB9ANPC1RECQLALDH1A1LMNA | |
| SCHEMBL2436211 | 0.80 | ALDH1A1 (0.79) | RAB9ANPC1RECQLALDH1A1LMNA | |
| SCHEMBL9187561 | 0.79 | NPC1 (1.00) | RAB9ANPC1RECQLALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | NEWAVE PHARMACEUTICAL INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4110298-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-115484933-A | Hot melt extrusion solid dispersions containing BCL2 inhibitors | 广州麓鹏制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021066873-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020041406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-6933390-B2 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | WARNER-LAMBERT COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040249185-A1 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | BARTH HUBERT (DE) | 2004-12-09 | — | — | US | disclosed |
| US-6774242-B1 | REACTING WITH INDOLE IN APROTIC SOLVENT | GOEDECKE GMBH (DE) | 2004-08-10 | — | — | US | disclosed |
| EP-1165512-A2 | METHOD FOR ARYLATING AZA-HETEROCYCLES WITH ACTIVATED AROMATIC COMPOUNDS IN THE PRESENCE OF CESIUM CARBONATE | GÖDECKE GMBH (DE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059883-A2 | METHOD FOR PRODUCING N-ARYL-AZA-HETEROCYCLES IN THE PRESENCE OF CESIUM CARBONATE | Gödecke GmbH (DE) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | BCL2, BCL2L1, BCL2L2 | RAB9A 932/4885NPC1 2558/4885RECQL 302/4885 |
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | RAB9A 478/4885NPC1 3788/4885RECQL 127/4885 |
| US-20040249185-A1 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | AZI2, KCNH1, CA7 | RAB9A 1479/4885NPC1 3071/4885RECQL 3995/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | RAB9A 478/4885NPC1 3788/4885RECQL 127/4885 |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | RAB9A 884/4885NPC1 3924/4885RECQL 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.